E-mail:BD@ebraincase.com
Tel:+8618971215294
English 中文版
Virus Vector - Viral Vector Production - BrainCaseVirus Vector - Viral Vector Production - BrainCase
  • Home
  • Virus product library
    CRISPRRNAiHSV-helperRV-helperNeurophilic virusCalcium SensorsOptogenetics activationOptogenetics inhibitionChemical geneticsSparse labelingFluorescent proteinBiosensorsRecombinaseApoptosis & AutophagyDisease ModelNeurotoxicityOther
  • Products & Service

    Product Center

    Virus

    VSV-circuit research-vaccine and gene therapy research-BrainCase
    Retrovirus-RCAS-TVA-BrainCase
    Lentivirus Vector - Lentivirus Production - BrainCase
    Rabies Virus Vector - RBV Vector - BrainCase
    Herpes simplex virus-Oncolytic and anterograde tracing-Brain Case
    PRV-retrograd multisynaptic-Peripheral-Btain Case
    AAV-gene therapy vectors-BrainCase

    Animal Model

    Neurological Disease Models-BrainCase
    Tumor animal models-anti-tumor-BrainCase
    Digestive System Disease Animal Model-Brain Case
    Cardiovascular System Disease Animal Models-Brain Case

    Plasmid Construction

    Bac
    Library Construction
    Plasmid design and construction

    Popular Applications

    Gene Regulation

    Gene Overexpression-Brain Case
    RNA interference(RNAi)-siRNA-Brain Case
    Gene Editing - CRSIPR cloning - BrainCase

    Neural Circuit Function Research

    Optogenetics - BrainCase
    Chemical genetics-DREADDs-Brain Case
    Calcium signal recording-Gels- Brain Case
    GRAB Neurotransmitter Fluorescent Probe- Brain Case
    Functional Magnetic Resonance Imaging Technology- Brain Case

    Research on the structure of neural circuits

    Direct Input and Output-viral vectors- Brain Case
    Anterograde Mono-synaptic Tracing -HSV- Brain Case
    Antrograde Muti-synaptic Tracing-HSV & VSV-Brain Case
    Retrograde Mono-synaptic Tracing-Rabies Virus-Brain Case
    Retrograde Muti-synaptic Tracing-PRV-Brain Case

    Featured Services

    Nervous System Disease Drug Effect

    Alzheimer's disease-AD-Brain Case
    Depression-mental disorders-Brain Case
    Parkinson's disease--PD-Brain Case
    Epilepsy-an ancient neurological disorder-Brain Case

    AAV Serotype Screening

    AAV Serotypes screening-gene therapy-Brain Case

    Tumorigenicity Test

    Tumorigenicity Testing-Evaluation of tumor models-Brain Case

    Efficacy of Oncolytic Virus

    Oncolytic virus-for cancer therapy-Brain Case
    Herpes Virus Vector-anti-tumor- BrainCase
    Vesicular stomatitis virus-killing tumor cells-Brain Case
  • News
    Corporate News New Product Launch Media Activity Investor News
  • Support
    Literature interpretation Customer article Video Zone FAQs
  • About Us
    Virus product library Products & Service News Support About Us Contact
  • Contact
    Contact Us Join us
  • 中文
    English 中文版
  • Home
  • Support
  • FAQs
  • Gene Regulation
  • FAQs
  • Animal experiments
  • Gene Regulation
  • Neural-circuit
  • Cell Experiments
  • Learning Center

Gene Regulation

  • Q1: What are the factors that affect siRNA transfection efficiency?

    A: The siRNA transfection efficiency is not ideal. Common reasons include the following aspects:

    1) The ratio of RNA to transfection reagent is not good. Due to differences in RNA sequences, different synthesis conditions, and whether it is labeled with fluorescence or other markers, RNA and transfection reagents will have different optimal conditions under different circumstances. It is recommended to conduct preliminary experiments first. optimization.

    2) The cell density is not good. Adjust the cell density to a confluency of 20-40% during transfection. Cells that are successfully transfected with siRNA will have down-regulation of target gene expression, but cells that are not successfully transfected will not be affected. At this time, the transfection efficiency and the total number of cells are very important. Generally, the transfection efficiency is high when the number of cells is small. Due to the timeliness of siRNA silencing, qRT-PCR detection can only be performed 48 hours after transfection, and protein detection can only be performed 48-72 hours after transfection. If the plating density is high during transfection, on the one hand, the transfection effect of the cells will not be ideal, which directly affects the silencing effect and data reliability. On the other hand, after 48 hours or even longer, when the optimal point of silencing detection is reached, the cells will be too dense. will affect the cell state and thus the experimental results.

    3) The RNA efficiency is not high. Select the optimal RNA during the experiment and use known efficient RNA as a control. When synthesizing siRNA, attention must be paid to selecting high-purity siRNA. The purity of siRNA is directly related to transfection efficiency and silencing efficiency.

    4) If the transfection reagent is not suitable, replace the transfection reagent, or choose a reagent specifically designed for siRNA transfection, such as Entranster reagent.

  • Q2: What factors need to be considered when designing stable strain construction experiments?

    A: Several key factors that need to be considered in a stable integration test are:

     

    1) In most cases, low copy or even single copy can reduce the interference of artificial experimental factors in most cases;

    2) The probability of foreign gene integration not only determines the difficulty of screening stable strains, but also makes it easier to obtain mixed stable strains;

    3) The transcription activity of the integration site determines the expression quality of the foreign fragment in the stable strain;

    4) Stability after integration Different integration sites determine the stability of the exogenous fragment in the chromosome. Some areas are prone to recombination or loss, resulting in the loss of stable strains again;

    5) Use mixed stable strains or obtain multiple different monoclonal stable strains. Because stable integration is often accompanied by insertion and inactivation of host endogenous genes, you can use mixed stable strains or compare multiple monoclonal stable strains during experiments. Help obtain more accurate experimental data.

  • Q3: How to improve RNA cell transfection efficiency?

    A:

    1) Purify RNA. Confirm the size and purity of RNA before transfection. To obtain high-purity RNA, it is recommended to use glass fiber to bind, elute or pass through 15-20% acrylamide gel to remove excess nucleotides, small oligonucleotides, proteins and salt ions in the reaction. Note: Chemically synthesized RNA usually requires gel electrophoresis purification (i.e. PAGE gel purification).

    2) Avoid RNase contamination. Trace amounts of RNase will cause RNA experiments to fail. Since RNase is ubiquitous in the experimental environment, such as skin, hair, all items touched by bare hands or exposed to the air, it is very important to ensure that every step of the experiment is free from RNase contamination.

    3) Healthy cell culture and strict operations ensure reproducibility of transfection. Generally, healthy cells have higher transfection efficiency. In addition, lower passage numbers ensure the stability of cells used in each experiment. In order to optimize the experiment, it is recommended to use transfected cells below 50 generations, otherwise the cell transfection efficiency will decrease significantly over time.

  • Q4: What problems may arise during vector construction?

    A: Common experimental errors in vector construction:

    1) Using the wrong enzyme during double enzyme digestion;

    2) For double enzyme digestion, the two enzyme digestion sites are too close;

    3) The sticky ends generated by enzyme digestion can be complementary;

    4) Use methylation-sensitive restriction endonucleases, such as Dpnll;

    5) Improper selection of host bacteria, such as using a strain containing F plasmid in Gateway cloning;

    6) Use high copy number backbones to clone large fragments. For example, plasmids have a high relative copy number but the loading capacity is up to 30 kb, AAV has a minimum relative copy number of 4.7 kb and a high relative copy number, and lentivirus has a relative copy number but the loading can be stable at 9,2 kb.

  • Q5: Which method is better, RNAi-mediated gene downregulation or CRISPR genome editing-mediated gene knockout?
    A: It depends on the specific experimental purpose. Among them, RNAi-mediated gene downregulation is more suitable than genome editing when there is no need to change the genetic code. However, to create a truly null allele on a chromosome, CRISPR genome editing is better.
map
{dede:global.cfg_webname/}

Virus product library

CRISPR
RNAi
Neurophilic virus
Optogenetics activation
Biosensors

News

Corporate News
New Product Launch
Media Activity
Investor News

Support

Literature interpretation
Customer article
Video Zone
FAQs
微信

WhatsApp Business Account

Tel: +8618971215294
E-mail: BD@ebraincase.com

Address:-

Address:-

  • Copyright © 2024 Brain Case All Rights Reserved.